USPTO 2015–2025 USPTO PatentsView US Corporation

Biogen MA Inc.

USPTO PatentsView assignee record — 247 granted patents across 39 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

247
Total patents granted
39
CPC technology areas
19.6
Avg claims per patent
-4%
5-year filing velocity

Portfolio overview

Biogen MA Inc. has been granted 247 US utility patents between 2015 and 2025, placing Biogen MA Inc. at rank #1,662 across all assignees tracked by PlainPatent. This portfolio spans 39 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Biogen MA Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 57.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 121 grants, compared with 126 in the 2015–2019 window — a -4% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Biogen MA Inc.'s 19.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 39 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Biogen MA Inc. against peers pursuing similar technology classes.

How does Biogen compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Biogen holds 247 patents — placing it at rank #1,662 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

10203040 20152016201720182019202020212022202320242025 14
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Biogen MA Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 12 4.9%
2016 24 9.7%
2017 38 15.4%
2018 21 8.5%
2019 31 12.6%
2020 20 8.1%
2021 34 13.8%
2022 21 8.5%
2023 18 7.3%
2024 14 5.7%
2025 14 5.7%

Which technologies does Biogen MA Inc. patent most?

Top 15 of 39 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#1,662

Across all tracked assignees

Innovation Score

57.0 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Biogen MA Inc. hold?
Biogen MA Inc. holds 247 US granted patents filed between 2015 and 2025, spanning 39 technology areas.
What is Biogen MA Inc.'s Innovation Score?
Biogen MA Inc. has an Innovation Score of 57.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Biogen MA Inc. focus on?
Biogen MA Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 152 patents. The company has filed patents in 39 CPC subclasses total.
Is Biogen MA Inc.'s patent filing rate increasing or decreasing?
Biogen MA Inc.'s recent filing velocity is -4% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Biogen MA Inc.'s patents?
Biogen MA Inc.'s patents average 19.6 claims each. This falls within the standard range, providing solid legal coverage.
How is the Biogen MA Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope